Publication: Nazofarenks karsinomlarında tedavi yaklaşımımız: Ön çalışma sonuçları
Abstract
Amaç: Nazofarenks karsinomunda uyguladığımız radyoterapi ve kemoterapi kombinasyonu tedavisinin ön çalışma sonuçlarının ortaya konulması. Gereç ve Yöntem: 1995-1999 yılları arasında nazofarenks karsinomu tanısı alan ve kliniğimizde cisplatin ve 5-florourasil kemoterapisi ve radyoterapi alan 22 olgu retrospektif ve prospektif olarak incelenerek tedavi sonuçları bildirilmektedir.Bulgular: Kemoterapi ve radyoterapi kombinasyon tedavisi uygulanan ve tedavisi tamamlanan 20 olguda ortalama yaşam süresi 46 ay ve hastalıksız yaşam süresi 24 aydır. Bir olguda bölgesel nüks, diğer bir olguda ise uzak metastaz gelişmiştir. Olgulardan 21'i hayattadır.Sonuç: Nazofarenks karsinomunun bilinen primer tedavisi radyoterapidir. Kemoterapinin rolü hakkında çeşitli sonuçlar bildirilmekle birlikte, kemoterapi ve radyoterapi kombinasyonunun surviyi arttırdığı belirtilmektedir. Ön çalışmamızda, tedavisi tamamlanan 20 olgudan 18'i (%90) hastalıksız olarak yaşamına devam etmektedir. Kemoterapi-radyoterapi kombinasyonunun sonuçlarının ortaya konulması için daha geniş çalışmalara ihtiyaç vardır.
Objectives: To evaluate the results of combined treatment with chemotherapy and radiotherapy in nasopharyngeal carcinoma. Materials and Methods: Twenty-two cases with nasopharyngeal carcinoma treated with combined cisplatinum and 5-fluorouracil chemotherapy and radiotherapy between 1995-1999. These cases were retrospectively analyzed and their treatment outcomes have been documented. Results: Combined chemotherapy and radiotherapy treatment have been completed in 20 cases. The mean survival was 46 months and the mean disease free survival was 24 months. In one case regional metastasis and in another case distant metastases have been documented. Twenty-one cases are still alive. Conclusion: Radiation therapy is the mainstay of treatment for nasopharyngeal carcinoma. Although there are controversial results about the role of chemotherapy in the treatment of nasopharyngeal carcinoma, the combined radiotherapy and chemotherapy improved survival. In our series, eighteen cases (90%) were disease free. Large series are needed to assess the effects of combined chemotherapy and radiotherapy.
Objectives: To evaluate the results of combined treatment with chemotherapy and radiotherapy in nasopharyngeal carcinoma. Materials and Methods: Twenty-two cases with nasopharyngeal carcinoma treated with combined cisplatinum and 5-fluorouracil chemotherapy and radiotherapy between 1995-1999. These cases were retrospectively analyzed and their treatment outcomes have been documented. Results: Combined chemotherapy and radiotherapy treatment have been completed in 20 cases. The mean survival was 46 months and the mean disease free survival was 24 months. In one case regional metastasis and in another case distant metastases have been documented. Twenty-one cases are still alive. Conclusion: Radiation therapy is the mainstay of treatment for nasopharyngeal carcinoma. Although there are controversial results about the role of chemotherapy in the treatment of nasopharyngeal carcinoma, the combined radiotherapy and chemotherapy improved survival. In our series, eighteen cases (90%) were disease free. Large series are needed to assess the effects of combined chemotherapy and radiotherapy.